lly manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme, Kuvan and Firdapse; actual sales of Aldurazyme, Naglazyme Kuvan and Firdapse; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2009 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.
Firdapse™ is a trademark of BioMarin Huxley Ltd.
Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.
Contact: InvestorsEugenia ShenBioMarin Pharmaceutical Inc.(415) 506-6570BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(In thousands, except for share and per share data)December 31, 2009 (1)September 30, 2010(unaudited)ASSETSCurrent assets:Cash and cash equivalents$
127,539Short-term investments133,506224,428Accounts receivable, net73,54078,734Inventory78,66291,741Other current assets14,84831,747Total current assets467,727554,189Investment in BioMarin/Genzyme LLC4411,161Long-term investments169,84988,955Property, plant and equipment, net199,141213,755Intangible assets, net40,977104,604Goodwill23,72253,364Other ass
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related medicine technology :1
|SOURCE BioMarin Pharmaceutical Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. BioMarin to Host a Research and Development Day on October 19th2
. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors3
. BioMarin to Present at the UBS Global Life Sciences Conference4
. BioMarin to Present at the Stifel Nicolaus Healthcare Conference5
. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease6
. BioMarin Acquires ZyStor Therapeutics, Inc.7
. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU8
. BioMarin to Acquire LEAD Therapeutics9
. BioMarin to Present at the Credit Suisse Healthcare Conference10
. BioMarin Announces Third Quarter 2009 Financial Results11
. BioMarin to Present at the Oppenheimer Healthcare Conference